Your browser doesn't support javascript.
loading
Refractory Thrombocytopenia Is a Valid Early Diagnostic Criteria for Hepatic Veno-Occlusive Disease in Children.
Embaby, Mostafa M; Rangarajan, Hemalatha G; Abu-Arja, Rolla; Auletta, Jeffery J; Stanek, Joseph; Pai, Vinita; Nicol, Kathleen K; Bajwa, Rajinder S.
Affiliation
  • Embaby MM; Department of Pediatrics, Hematology Unit, Children's University Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt; Department Of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.
  • Rangarajan HG; Department Of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.
  • Abu-Arja R; Department Of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.
  • Auletta JJ; Department Of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.
  • Stanek J; Department Of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.
  • Pai V; Department of Clinical Pharmacy, Nationwide Children's Hospital, Columbus, Ohio.
  • Nicol KK; Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio.
  • Bajwa RS; Department Of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio. Electronic address: rajinder.bajwa@nationwidechildrens.org.
Biol Blood Marrow Transplant ; 26(3): 546-552, 2020 03.
Article in En | MEDLINE | ID: mdl-31756537
We compared the incidence of refractory thrombocytopenia (RT) and platelet transfusion requirements (PTR) in 35 children who developed veno-occlusive disease (VOD) with 35 matched control subjects who underwent hematopoietic stem cell transplant but did not develop VOD. RT developed in 100% of the VOD patients, at a median of 8 days before VOD diagnosis, as compared with 71.5% of the control group. VOD patients required more platelet transfusions than control subjects (median PTR, 6.9 mL/kg [range, .57 to 17.59] versus 3.57 mL/kg [range, 0 to 14.63], respectively) with a statistically significant difference (P < .0001). The number of days with platelet requirements was significantly higher for VOD patients as compared with control subjects (median 68% versus 39%, P =< .0001). The PTR peaked at ~12 mL/kg/day, 2 days before VOD diagnosis, whereas the PTR in the control population was 5 mL/kg/day. The positive predictive value of developing VOD was 88.9% (95% confidence interval, 66.5% to 97%) in patients who were given >7 mL/kg/day of platelets during the at-risk period of days +3 to +13 after transplant. For patients who received >8 mL/kg/day of platelets, the positive predictive value of developing VOD was 86.7% (95% confidence interval, 61.2% to 96.4%). There was no difference in the PTR in patients with mild to moderate VOD as compared with severe VOD; however, the PTR was higher in patients whose VOD did not resolve. The median daily PTR after the diagnosis of VOD in 17 patients who got defibrotide as compared with those who did not get defibrotide was 6.04 mL/kg and 5.72 mL/kg, respectively, but the difference was not statistically significant (P = .56). On univariate and multivariate analysis use of intravenous immunoglobulin was significantly associated with VOD (P = .0088) but was not significantly associated with fatal VOD. In conclusion, RT occurs in 100% of patients at a median of 8 days before VOD diagnosis. VOD should be suspected in any patient with RT after the exclusion of other causes of consumptive thrombocytopenia, especially if they require >7 mL/kg/day of platelets.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Thrombocytopenia / Hepatic Veno-Occlusive Disease / Hematopoietic Stem Cell Transplantation Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Child / Humans Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Thrombocytopenia / Hepatic Veno-Occlusive Disease / Hematopoietic Stem Cell Transplantation Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Child / Humans Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2020 Type: Article